PMID: 6113858Apr 1, 1981Paper

Bioavailability of terfenadine in man

Biopharmaceutics & Drug Disposition
R A OkerholmC E Cook

Abstract

Fourteen normal male subjects were given either 60mg or 180mg of terfenadine suspension in a randomized two-way crossover study. Peak plasma concentrations of 1.544 +/- 0.726 (mean +/- S.D.) ng ml-1 were obtained in 0.786 h following the 60 mg dose and displayed an AUC or 11.864 +/- 3.369 ng h ml-1. Whereas peak plasma concentrations of 4.519 +/- 2.002 ng ml-1 in 1.071 +/- 0.514 h were obtained following the 180 mg dose. The AUC following the 180 mg dose was 44.341 +/- 22.041 ng h ml-1. When 60 mg of 14C terfenadine was given to six additional subjects, the peak plasma concentrations of 351 +/- 43 ng equivalents per ml were obtained in 1.67 +/- 0.41 h and the AUC was 2297.71 +/- 310.85 ng-equivalents h ml-1. This indicates that approximately 99.5 per cent of the terfenadine related material that is absorbed undergoes biotransformation. Urinary excretion of 14C accounted for 39.89 +/- 5.29 per cent of the dose while 60.58 +/- 2.44 per cent of the dose was recovered in the feces in twelve days. Thin-layer chromatographic (TLC) examination of fecal extracts showed only a trace of material chromatographing with terfenadine. This may indicate that the 14C present in the feces is not due to lack of absorption.

References

Nov 14, 1977·European Journal of Clinical Pharmacology·K J HütherJ Koch-Weser
Jul 1, 1978·British Journal of Clinical Pharmacology·V K KulshresthaJ Wadsworth
Dec 1, 1978·European Journal of Clinical Pharmacology·A ReinbergA Nicolai
Jan 1, 1979·Pharmakopsychiatrie, Neuro-Psychopharmakologie·M Fink, P Irwin
Dec 1, 1980·Journal of Pharmaceutical Sciences·C E CookG J Wright

❮ Previous
Next ❯

Citations

Dec 6, 2011·Archives of Pharmacal Research·Young Hee ChoiYoon Gyoon Kim
Apr 1, 1997·Clinical Biochemistry·J U EskolaT Korpela
Jun 6, 2000·Advanced Drug Delivery Reviews·D D ShenK E Thummel
Dec 14, 2002·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·J L C M DorneA G Renwick
Mar 19, 2002·American Journal of Therapeutics·Robert R Fenichel
Feb 4, 1989·BMJ : British Medical Journal·A J DaviesR R Ghose
Aug 12, 2003·Clinical Pharmacokinetics·Megan A Gibbs, Natilie A Hosea
Feb 16, 2005·Expert Opinion on Drug Safety·Rashmi R Shah
Jan 11, 1991·Chirality·K ZamaniL R Cantilena
Aug 1, 1997·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·N BenlounesM Heyman
Oct 1, 1996·Journal of Pharmacokinetics and Biopharmaceutics·G R Wilkinson
Nov 1, 2008·Drug Metabolism and Pharmacokinetics·Yoshihiro ShibataYasuyuki Ishii
Nov 19, 2014·Analytical and Bioanalytical Chemistry·Line Rørbæk OlsenChristian Janfelt
Jun 23, 1999·Mayo Clinic Proceedings·S Alvarez-Elcoro, M J Enzler
Sep 1, 1989·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·M NabeR G Townley
Aug 1, 1990·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·F E Simons
Oct 1, 1993·The American Review of Respiratory Disease·S MyouT Matsuda
May 13, 2006·The Journal of Pharmacology and Experimental Therapeutics·Ryan Z TurncliffKim L R Brouwer
Nov 1, 1985·Drug Intelligence & Clinical Pharmacy·C A CarterL A Rickman
Jan 2, 1988·British Medical Journal·K F Chung, P J Barnes
Feb 1, 1986·Postgraduate Medicine·D E Schuller, D Turkewitz
Jan 1, 1985·The Journal of International Medical Research·J P GirardS A Henauer

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.